Influenza [strain A/H7N9] vaccine is under clinical development by EpiVax and currently in Phase II for Influenza A Virus, H7N9 Subtype Infections. According to GlobalData, Phase II drugs for Influenza A Virus, H7N9 Subtype Infections does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Influenza [strain A/H7N9] vaccine LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Influenza [strain A/H7N9] vaccine overview

Vaccine for the avian influenza A (H7N9) virus is under development. This vaccine comprises of the antigen hemagglutinin (HA). Haemagglutinin is an antigenic glycoprotein derived from human-derived H7N9 strains contains T cell epitopes. It is administered through intramuscular route. 

EpiVax overview

EpiVax develops analytical capabilities in the field of computational immunology. Its product pipeline includes Tregitopes; deimmunization projects including deimmunized botox and deimmunized FVIII; and biodefense vaccines. Tregitopes are linear sequences of amino acids which activate natural regulatory T cells. It is an immune-modulation power tool that is being developed for auto-immune, auto-inflammatory and allergic conditions. EpiVax’ service portfolio includes immune engineering, immunogenicity screening, vaccine design, and redesign. It also provides lab services such as in vivo, in vitro and ex vivo immunogenicity screening services including cell-free HLA binding assays. EpiVax is headquartered in Providence, Rhode Island, the US.

For a complete picture of Influenza [strain A/H7N9] vaccine’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 22 April 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.